Comparison of Different Histone Deacetylase Inhibitors in Attenuating Inflammatory Pain in Rats
Authors:
Open Access
- 27 January 2019
- journal article
- research article
- Published by Wiley in Pain Research and Management
- Vol. 2019, 1-10
Abstract
Histone deacetylase inhibitors (HDACIs), which interfere with the epigenetic process of histone acetylation, have shown analgesic effects in animal models of persistent pain. The HDAC family comprises 18 genes; however, the different effects of distinct classes of HDACIs on pain relief remain unclear. The aim of this study was to determine the efficacy of these HDACIs on attenuating thermal hyperalgesia in persistent inflammatory pain. Persistent inflammatory pain was induced by injecting Complete Freund’s Adjuvant (CFA) into the left hind paw of rats. Then, HDACIs targeting class I (entinostat (MS-275)) and class IIa (sodium butyrate, valproic acid (VPA), and 4-phenylbutyric acid (4-PBA)), or class II (suberoylanilide hydoxamic acid (SAHA), trichostatin A (TSA), and dacinostat (LAQ824)) were administered intraperitoneally once daily for 3 or 4 days. We found that the injection of SAHA once a day for 3 days significantly attenuated CFA-induced thermal hyperalgesia from day 4 and lasted 7 days. In comparison with SAHA, suppression of hyperalgesia by 4-PBA peaked on day 2, whereas that by MS-275 occurred on days 5 and 6. Fatigue was a serious side effect seen with MS-275. These findings will be beneficial for optimizing the selection of specific HDACIs in medical fields such as pain medicine and neuropsychiatry.Keywords
Funding Information
- National Natural Science Foundation of China (31600851)
This publication has 74 references indexed in Scilit:
- The individual and societal burden of chronic pain in Europe: the case for strategic prioritisation and action to improve knowledge and availability of appropriate careBMC Public Health, 2013
- HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic painPain, 2013
- Epigenetic suppression of GAD65 expression mediates persistent painNature Medicine, 2011
- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapyClinical Epigenetics, 2010
- Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myelomaCancer, 2010
- Inhibition of Class II Histone Deacetylases in the Spinal Cord Attenuates Inflammatory HyperalgesiaMolecular Pain, 2010
- Multiple roles of HDAC inhibition in neurodegenerative conditionsTrends in Neurosciences, 2009
- Histone Deacetylase Inhibitor MS-275 Exhibits Poor Brain Penetration: Pharmacokinetic Studies of [11C]MS-275 using Positron Emission TomographyACS Chemical Neuroscience, 2009
- Histone deacetylase inhibitors decrease Toll‐like receptor‐mediated activation of proinflammatory gene expression by impairing transcription factor recruitmentImmunology, 2007
- Evidence of Endogenous Mu Opioid Receptor Regulation by Epigenetic Control of the PromotersMolecular and Cellular Biology, 2007